SEC Comment Letter 0000000000-24-012656 to CATALYST PHARMACEUTICALS, INC. (CPRX) (CIK 0001369568) (CPRX)
CATALYST PHARMACEUTICALS, INC. (CPRX) (CIK 0001369568)
Date: Nov. 15, 2024 · CIK: 0001369568 · Accession: 0000000000-24-012656
AI Filing Summary & Sentiment
File numbers found in text: 001-33057
Letter
November 15, 2024 Michael W. Kalb EVP and Chief Financial Officer CATALYST PHARMACEUTICALS, INC. 355 Alhambra Circle Suite 801 Coral Gables, FL 33134 Re:CATALYST PHARMACEUTICALS, INC. Form 10-Q for the period ending June 30, 2024 Filed August 7, 2024 Form 8-K filed February 29, 2024 File No. 001-33057 Dear Michael W. Kalb: We have completed our review of your filings. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
November 15, 2024
Michael W. Kalb
EVP and Chief Financial Officer
CATALYST PHARMACEUTICALS, INC.
355 Alhambra Circle
Suite 801
Coral Gables, FL 33134
Re:CATALYST PHARMACEUTICALS, INC.
Form 10-Q for the period ending June 30, 2024
Filed August 7, 2024
Form 8-K filed February 29, 2024
File No. 001-33057
Dear Michael W. Kalb:
We have completed our review of your filings. We remind you that the company and
its management are responsible for the accuracy and adequacy of their disclosures,
notwithstanding any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences